Pathstone Family Office’s Amedisys AMED Stock Holding History

Pathstone Family Office’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,183	Closed	-$212K	–	1497
2022 Q3	$212K	Buy	+2,183	New	+$260K	﹤0.01%	1325

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Pathstone Family Office's AMED Position: Q4 2022 in Review

Pathstone Family Office sold out of Amedisys (AMED) in Q4 2022, closing a stake of 2,183 shares — an estimated $212K sold.

Pathstone Family Office first reported a position in AMED in Q3 2022 and held it in 1 quarter. The position peaked at $212K in Q3 2022. 277 funds tracked by Wall St. Rank hold AMED as of Q4 2022.

Pathstone Family Office reported no remaining Amedisys position as of Q4 2022 after selling out during the quarter.
Pathstone Family Office sold 2,183 Amedisys shares in Q4 2022, an estimated $212K.
Pathstone Family Office first reported a position in Amedisys in Q3 2022 and held it in 1 quarter.
Pathstone Family Office's Amedisys position peaked at $212K in Q3 2022.
277 funds tracked by Wall St. Rank held Amedisys as of Q4 2022.

Based on Pathstone Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.